Literature DB >> 19387842

Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Yelena Krupitskaya1, Billy W Loo.   

Abstract

High-level evidence to guide the optimal postoperative management of patients with completely resected non-small-cell lung cancer (NSCLC) is lacking. Large randomized controlled trials have established postoperative chemotherapy as the standard of care for patients with pathologically involved lymph nodes. Recent retrospective and non-randomized studies provide evidence of the benefit of post-operative radiation therapy (PORT) in patients with mediastinal nodal involvement (N2 stage). A large multi-institutional randomized trial of PORT in this patient population is now underway. Based on currently available data, PORT may be considered for fit patients with completely resected NSCLC with N2 nodal involvement, preferably after completion of adjuvant chemotherapy. At this point, PORT is not recommended for patients with less than N2 nodal stage. Ideally, modern three-dimensional conformal radiation technique should be used, with attention to normal organ sparing, particularly lung and heart. Appropriate image guidance tools are encouraged to individualize treatment margins, account for breathing-induced motion, and minimize irradiation of normal tissues. The target volume should include at a minimum the bronchial stump, ipsilateral hilum, and involved nodal stations, and covering adjacent mediastinal nodal stations is recommended. A total dose of 50-54 Gy in 1.8-2 Gy fractions is appropriate.

Entities:  

Mesh:

Year:  2009        PMID: 19387842     DOI: 10.1007/s11864-009-0090-8

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  54 in total

1.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.

Authors:  S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

2.  4D-CT imaging of a volume influenced by respiratory motion on multi-slice CT.

Authors:  Tinsu Pan; Ting-Yim Lee; Eike Rietzel; George T Y Chen
Journal:  Med Phys       Date:  2004-02       Impact factor: 4.071

Review 3.  Lung toxicity following chest irradiation in patients with lung cancer.

Authors:  Raymond P Abratt; Graeme W Morgan
Journal:  Lung Cancer       Date:  2002-02       Impact factor: 5.705

4.  Non-small cell lung cancer.

Authors:  David S Ettinger; Wallace Akerley; Gerold Bepler; Andrew Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Steven J Feigenberg; Robert A Figlin; Ramaswamy Govindan; Frederic W Grannis; Thierry Jahan; Mohammad Jahanzeb; Anne Kessinger; Ritsuko Komaki; Mark G Kris; Corey J Langer; Quynh-Thu Le; Renato Martins; Gregory A Otterson; Jyoti D Patel; Francisco Robert; David J Sugarbaker; Douglas E Wood
Journal:  J Natl Compr Canc Netw       Date:  2008-03       Impact factor: 11.908

5.  A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques.

Authors:  B Dautzenberg; R Arriagada; A B Chammard; A Jarema; M Mezzetti; K Mattson; J L Lagrange; C Le Pechoux; B Lebeau; C Chastang
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

6.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database.

Authors:  Brian E Lally; Daniel Zelterman; Joseph M Colasanto; Bruce G Haffty; Frank C Detterbeck; Lynn D Wilson
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

7.  Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis.

Authors:  A Inoue; H Kunitoh; I Sekine; M Sumi; K Tokuuye; N Saijo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Quantification of motion of different thoracic locations using four-dimensional computed tomography: implications for radiotherapy planning.

Authors:  Peter G Maxim; Billy W Loo; Haider Shirazi; Brian Thorndyke; Gary Luxton; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-14       Impact factor: 7.038

10.  Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung.

Authors: 
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

View more
  3 in total

Review 1.  Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).

Authors:  Bojan Zaric; Vladimir Stojsic; Aleksandar Tepavac; Tatjana Sarcev; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Ilias Karapantzos; Georgios Kesisis; Ioanna Kougioumtzi; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Aikaterini Stylianaki; Christophoros N Foroulis; Konstantinos Zarogoulidis; Branislav Perin
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

2.  Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer.

Authors:  Takeshi Hanagiri; Masaru Takenaka; Soich Oka; Yoshiki Shigematsu; Yoshika Nagata; Hidehiko Shimokawa; Hidetaka Uramoto; Fumihiro Tanaka
Journal:  J Cardiothorac Surg       Date:  2011-10-25       Impact factor: 1.637

3.  Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer.

Authors:  Xuquan Jing; Xue Meng; Xindong Sun; Jinming Yu
Journal:  Onco Targets Ther       Date:  2016-02-19       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.